NCT05563675CompletedPhase 4
Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause
Comparing Morning and Evening Dosing of Inhaled Long-Acting Muscarinic Antagonists for the Prevention of Hospitalization Requiring AECOPD or Death from All Causes - the LAMA by Night Study Utilizing a Comprehensive Nationwide Digital Platform for Recruitment Into a Pragmatic Randomized Controlled Trial Integrated with National Registries to Follow Outcomes
Source: ClinicalTrials.gov · Last updated 19 Feb 2025
Brief summary (registry, in English)
To examine, among once-daily LAMA using COPD patients, whether evening administration of LAMA is superior with respect to the incidence of hospitalization requiring AECOPD or death from all causes than the more conventional morning administration.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 10011 (actual)
- First submitted
- 23 Sept 2022
- Start date
- 27 Jan 2023
- Primary completion date
- 1 Jun 2024
- Lead sponsor
- Chronic Obstructive Pulmonary Disease Trial Network, Denmark
- Diseases
- COPD
- NCT number
- NCT05563675
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 10011
- From 27 Jan 2023 to the primary completion date, 1 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. Patients who decline to participate.
Who the study is looking for
- Age more than or equal to 30 years
- Current treatment with LAMA once daily (as recorded in the Danish National Prescription Registry and confirmed by the participant via questionnaire)
- Self-reported COPD
Age in the registry: 30 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Herlev-Gentofte Hospital Coordinator of this site? Confirm its status | Copenhagen | Denmark | Unknown status |
Related publications
- Evening administration of long-acting muscarinic antagonists in COPD - a randomized controlled trial.BMC Pulm Med · 2025 · PMID 41340061
This page is information, not medical advice. Discuss any trial with your doctor.